These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26425251)

  • 41. Newer clinically available antithrombotics and their antidotes.
    Lévy S
    J Interv Card Electrophysiol; 2014 Sep; 40(3):269-75. PubMed ID: 24934756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
    Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
    Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dabigatran etexilate: management in acute ischemic stroke.
    Javedani PP; Horowitz BZ; Clark WM; Lutsep HL
    Am J Crit Care; 2013 Mar; 22(2):169-76. PubMed ID: 23455868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
    Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
    Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
    Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
    JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What is the Role of Reversal Agents in the Management of Emergency Department Patients with Dabigatran-Associated Hemorrhage?
    Hayes BD; Winters ME; Rosenbaum SB; Allehyani MF; Vilke GM
    J Emerg Med; 2018 Apr; 54(4):571-575. PubMed ID: 29456085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.
    Molteni M; Bo M; Di Minno G; Di Pasquale G; Genovesi S; Toni D; Verdecchia P
    Intern Emerg Med; 2017 Jun; 12(4):425-435. PubMed ID: 28439778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.
    Mack DR; Kim JJ
    Ann Pharmacother; 2012; 46(7-8):1105-10. PubMed ID: 22764329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dabigatran etexilate: what do hospitalists need to know?
    Zeidan A; Faltas B; Streiff M
    J Hosp Med; 2012 Mar; 7(3):262-9. PubMed ID: 22128108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.
    Nogami A; Harada T; Sekiguchi Y; Otani R; Yoshida Y; Yoshida K; Nakano Y; Nuruki N; Nakahara S; Goya M; Origasa H; Kihara Y; Hirao K; Aonuma K;
    JAMA Netw Open; 2019 Apr; 2(4):e191994. PubMed ID: 31002317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dabigatran: a review of clinical and pharmacoeconomic evidence.
    Reddy P; Atay JK; Selbovitz LG; Connors JM; Piazza G; Block CC; Arpino PA; Berliner N; Hutter AM; Fischer MA; Kuter D; Weitzman J; Sherwood GK; Almozlino A; Giugliano RP
    Crit Pathw Cardiol; 2011 Sep; 10(3):117-27. PubMed ID: 21989032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
    Frontera JA; Lewin JJ; Rabinstein AA; Aisiku IP; Alexandrov AW; Cook AM; del Zoppo GJ; Kumar MA; Peerschke EI; Stiefel MF; Teitelbaum JS; Wartenberg KE; Zerfoss CL
    Neurocrit Care; 2016 Feb; 24(1):6-46. PubMed ID: 26714677
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dabigatran etexilate in atrial fibrillation.
    Vora A
    J Assoc Physicians India; 2013 Dec; 61(12):900-2. PubMed ID: 24968547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.
    Manatsathit W; Al-Hamid H; Leelasinjaroen P; Hashmi U; McCullough PA
    Cardiovasc Diagn Ther; 2014 Jun; 4(3):224-31. PubMed ID: 25009791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience.
    Singh T; Maw TT; Henry BL; Pastor-Soler NM; Unruh ML; Hallows KR; Nolin TD
    Clin J Am Soc Nephrol; 2013 Sep; 8(9):1533-9. PubMed ID: 23704302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dabigatran and kidney disease: a bad combination.
    Knauf F; Chaknos CM; Berns JS; Perazella MA
    Clin J Am Soc Nephrol; 2013 Sep; 8(9):1591-7. PubMed ID: 23868901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.